ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
FU
Fudan University Shanghai Cancer Center at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Fudan University Shanghai Cancer Center takes part in 33 sessions at ESMO 2026 in Madrid. Its program centres on treatment strategies and biomarkers across many cancer types. It compares four versus six months of adjuvant XELOX for stage II–IIIB gastric cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
FU Fudan University Shanghai Cancer Center Shanghai, China | |
Cancer hospital of Fudan University in Shanghai, China. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Exploratory study of TP53 mutations in circulating tumor DNA as prognostic and longitudinal monitoring biomarkers for relapsed ovarian carcinoma patients Gynaecological cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Interim Analysis of the Reduce-01 Prospective Trial: Urine Cancer DNA for Re-TURBT Decision in NMIBC Patients Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 TP53-mutated/triple-negative subtypes and neutrophil depleted are unfavorable prognostic markers of adjuvant platinum-based chemotherapy:a prospective cohort study of Chinese upper tract urothelial carcinoma Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 15:15–16:00 A multi-organ single-nucleus atlas of metastatic clear cell renal cell carcinoma identifies MITF-driven regulatory programs Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Clinical validation of a tissue-based next-generation sequencing kit for identifying patients with BRCA1/2-mutated prostate cancer for niraparib + abiraterone acetate and prednisone therapy Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 First-in-human phase I study of AXT-1003, a novel EZH2 degrader, in patients with advanced solid tumors and relapsed/refractory NHL Haematological malignanciesGynaecological cancersSarcoma, CNS, head & neck and rare cancersLung & thoracic cancersBreast cancerGenitourinary cancers Poster Fri Oct 23 15:15–16:00 Abstract Fri Oct 23 16:15–16:20 Abstract Fri Oct 23 16:52–16:57 Abstract Fri Oct 23 17:10–17:15 Abstract Sat Oct 24 10:37–10:42 Abstract Sat Oct 24 10:45–10:50 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Satellite Sat Oct 24 13:15–13:35 PSMA-targeted RLT in mCRPC: From guidelines to everyday decisions Genitourinary cancers Talk Sun Oct 25 09:00 Poster Sun Oct 25 12:00–12:45 Circulating tumor DNA as a dynamic biomarker for recurrence monitoring in colorectal cancer peritoneal metastases: Interim analysis of the PEARL study Gastrointestinal cancersBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Multi-omics integration uncovers predictive biomarkers and causal targets in pan-cancer Biomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Talk Sun Oct 25 15:15–16:00 Abstract Sun Oct 25 15:17–15:22 Abstract Mon Oct 26 09:14–09:19 Abstract Mon Oct 26 10:20–10:25 Abstract Mon Oct 26 10:25–10:30 Abstract Mon Oct 26 10:30–10:35 Abstract Mon Oct 26 10:52–10:57 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Application of lenvatinib ± PD-1 inhibitors as a neoadjuvant treatment in locally advanced thyroid cancer: A multicenter, prospective, real-world study Sarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Filling the gap: A retrospective study on survival analysis by risk stratification in 236 aged ≥14 years rhabdomyosarcoma patients Sarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Poster Mon Oct 26 12:00–12:45 Abstract Mon Oct 26 14:45–14:55 4241O - Multi-omics profiling defines drivers, organotropism, and predictive models in RCC metastasis Biomarkers & precision oncology |
Find decision makers at Fudan University Shanghai Cancer Center
Tell us what you sell and we’ll find the people at Fudan University Shanghai Cancer Center most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction